|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer.
|
25262966 |
2015 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of BRAF V600E mutation in FNAC material is always associated with the presence of TC.
|
26884114 |
2016 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, BRAF(V600E) PTC tumors display a broadly immunosuppressive profile and evidence of disturbed host tumor immune surveillance that may contribute to the poorer outcomes observed in this subset of patients with thyroid cancer.
|
24955518 |
2014 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thyroid neoplasms with PD-L1 expression also ae enriched with BRAF V600E mutations, suggesting that they are associated with more aggressive behavior.
|
31821747 |
2020 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The T1799A activating point mutation is detected in >98% of the thyroid tumors, and result in substitution of amino acid valine at position 600 to glutamic acid.
|
30414980 |
2018 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Identification of BRAF(V600E) in thyroid neoplasia may be useful because it is specific for malignancy, connotes a worse prognosis, and is the target of novel therapies currently under investigation.
|
22997209 |
2012 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
|
27880942 |
2017 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the study was to explore TERT promoter mutations in various thyroid tumors and examine their relationship with BRAF V600E mutation, iodine intake, and clinicopathological behaviors of thyroid cancer.
|
24617711 |
2014 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mice with BRAF(V600E)-induced PTC will provide an excellent system to study thyroid tumor initiation and progression and the evaluation of inhibitors of oncogenic BRAF signaling.
|
21512141 |
2011 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Investigating BRAF((V600E)) inhibitors (BRAFi) as a strategy to treat patients with aggressive thyroid tumors harboring the BRAF((V600E)) mutant currently is in progress, and drug resistance is expected to pose a challenge.
|
26456124 |
2016 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutational status in pediatric thyroid cancer.
|
24677749 |
2014 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This represents a novel mechanism in BRAF V600E-promoted PTC aggressiveness and identifies WIPF1 as a novel therapeutic target for thyroid cancer.
|
27863429 |
2017 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Polymerase chain reaction was used to amplify exon 15 of the BRAF gene from paraffin-embedded thyroid tumor specimens, followed by direct sequencing to detect the BRAF(V600E) mutation.
|
22190222 |
2012 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
|
26857243 |
2016 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigates the expression of CYP24A1 and the effect of BRAF(V600E) on its expression in thyroid cancer.
|
24382015 |
2014 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Given the strong genotype:phenotype correlation known to be present in thyroid cancer, the separation of BRAF(V600E)-like and RAS-like tumors has profound implications for its classification, especially the follicular variant of papillary carcinoma.
|
26569424 |
2016 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is the most common genetic alteration in thyroid cancer.
|
25266729 |
2014 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer.
|
21185263 |
2011 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Matched blood and tissue assays for BRAF(V600E) were performed on 70 patients with PTC (stages I to IV, n = 48) or other (n = 22) thyroid tumors.
|
26631873 |
2016 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that fibroblasts were recruited to the TME of Braf(V600E)/Pten(-/-)/TPO-Cre thyroid tumors.
|
26818109 |
2016 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor characterized by frequent RAS mutations and an absence of the BRAF V600E mutation commonly seen in classical papillary thyroid carcinoma (cPTC).
|
29396809 |
2018 |